High frequency of BRAF mutations in nevi
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
To evaluate the timing of mutations in BRAF (v-raf murine sarcoma viral oncogene homolog B1) during melanocytic neoplasia, we carried out mutation analysis on microdissected melanoma and nevi samples. We observed mutations resulting in the V599E amino-acid substitution in 41 of 60 (68%) melanoma metastases, 4 of 5 (80%) primary melanomas and, unexpectedly, in 63 of 77 (82%) nevi. These data suggest that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, the BRAF oncogenic mutation found in more than half of all malignant cutaneous melanomas is commonly found also in non-malignant nevi, where it causes oncogene-induced senescence exemplified by high levels of CDKN2A and SA-β-gal expression225–227.”
From SenNet recommendations for detecting senescent cells in different tissues (2024) · cites this paper as [226]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Kononen, J., Bubendorf, L., Kallionimeni, A., Bärlund, M., Schraml, P., Leighton, S., Torhorst, J., Mihatsch, M. J., Sauter, G., & Kallionimeni, O.-P. (1998) · Nature Medicine · doi:10.1038/nm0798-844 · Cited by 4,099
Busca, R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.12.2900 · Cited by 326
The Regulation of Normal Melanocyte Proliferation
Halaban, R. (2000) · Pigment Cell Research · doi:10.1034/j.1600-0749.2000.130103.x · Cited by 179
Research works printed but not linked: 2
- Armstrong, B.K. & English, D.R. in Cancer Epidemiology and Prevention (Oxford University Press, New York, 1996).
- Elder, D.E. & Murphy, G.F. in Atlas of Tumor Pathology: Melanocytic Tumors of the Skin 5–101 (Armed Forces Insititute of Pathology, Washington, DC, 1991).
Cited by
Items 501–600 of 1,001
Kääriäinen, E., Nummela, P., Soikkeli, J., Yin, M., Lukk, M., Jahkola, T., Virolainen, S., Ora, A., Ukkonen, E., Saksela, O., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2045 · Cited by 66
Mar�n, Y. E., & Chen, S. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0566-8 · Cited by 69
“Recently, activating mutations of B-RAF in many human malignant melanomas have been reported [112, 113].”
BackgroundBrown, K., Yang, P., Salvador, D., Kulikauskas, R. M., Ruohola‐Baker, H., Robitaille, A. M., Chien, A. J., Moon, R. T., & Sherwood, V. (2017) · Oncogene · doi:10.1038/onc.2016.450 · Cited by 69
Dynamic Changes in Nevi of a Patient With Melanoma Treated With Vemurafenib
Haenssle, H. A., Kraus, S. L., Brehmer, F., Kretschmer, L., Völker, B., Asper, H., Kapp, A., & Gutzmer, R. (2012) · Archives of Dermatology · doi:10.1001/archdermatol.2012.2649 · Cited by 64
Kansal, R., Quintanilla‐Martínez, L., Datta, V., Lopategui, J. R., Garshfield, G., & Nathwani, B. N. (2012) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22010 · Cited by 68
Feller, J. K., Yang, S., & Mahalingam, M. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.168 · Cited by 65
The Cullin7 E3 ubiquitin ligase: A novel player in growth control
Sarikas, A., Xu, X., Field, L. J., & Pan, Z. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6922 · Cited by 74
Human Leukocyte Antigen-A2–Restricted CTL Responses to Mutated BRAF Peptides in Melanoma Patients
Somasundaram, R., Swoboda, R., Caputo, L., Ötvös, L., Weber, B. L., Volpe, P., Belle, P. A. V., Hotz, S., Elder, D. E., Marincola, F. M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1932 · Cited by 64
“expressed by 70% of specimens derived from melanoma patients ( 3 ), and the peptides described here have vaccine potential for HLA-A2+ melanoma patients (f50% of patients; ref.”
BackgroundKim, E., Rebecca, V., Fedorenko, I. V., Messina, J. L., Mathew, R., Maria-Engler, S. S., Basanta, D., Smalley, K. S. M., & Anderson, A. R. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1720 · Cited by 66
“nevi that harbor BRAF mutations (6) rarely undergo full malignant transformation.”
Choi, J., Xu, M., Makowski, M. M., Zhang, T., Law, M. H., Kovacs, M. A., Granzhan, A., Kim, W. J., Parikh, H. M., Gartside, M. G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3927 · Cited by 67
Self-citationConsistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status
Pappa, K. I., Choleza, M., Markaki, S. P., Giannikaki, E., Kyroudi, A., Vlachos, G. D., Voulgaris, Z., & Anagnou, N. P. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.09.029 · Cited by 64
The clinical application of autologous bioengineered skin based on a hyaluronic acid scaffold
Scuderi, N., Onesti, M. G., Bistoni, G., Ceccarelli, S., Rotolo, S., Angeloni, A., & Marchese, C. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2007.12.024 · Cited by 64
“The BRAF oncogene has been reported to be mutated at high frequencies in melanomas and among other carcinomas, as well as in a majority of melanoma cell lines [14].”
BackgroundBRAF as a melanoma susceptibility candidate gene?
Laud, K., Kannengiesser, C., Avril, M., Chompret, A., Stoppa‐Lyonnet, D., Desjardins, L., Eychène, A., Démenais, F., Lenoir, G., & Paillerets, B. B. (2003) · PubMed · Cited by 75
BRAFV600E Negatively Regulates the AKT Pathway in Melanoma Cell Lines
Chen, B., Tardell, C., Higgins, B., Packman, K. E., Boylan, J. F., & Niu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042598 · Cited by 75
Mutational analysis of the BRAF gene in human congenital and dysplastic melanocytic naevi
Papp, T., Schipper, H., Kumar, K., Schiffmann, D., & Zimmermann, R. (2005) · Melanoma Research · doi:10.1097/00008390-200510000-00008 · Cited by 68
BRAFV 600E mutation in the diagnosis of unicystic ameloblastoma
Pereira, N. B., Pereira, K. M. A., Coura, B. P., Diniz, M. G., Castro, W. H., Gomes, C. C., & Gomez, R. S. (2016) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12443 · Cited by 63
G‐protein‐coupled receptors and melanoma
Lee, H. J., Wall, B., & Chen, S. (2008) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2008.00478.x · Cited by 78
“Initially, we demonstrated GRM1 expression in seven of 19 melanoma biopsies and 12 of 18 human melanoma cell lines (Pollock et al., 2003a).”
BackgroundInfluentialIdentification of direct transcriptional targets of V600EBRAF/MEK signalling in melanoma
Packer, L. M., East, P., Reis‐Filho, J. S., & Marais, R. (2009) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2009.00618.x · Cited by 62
“Similarly, in humans up to 80% of benign naevi harbour a BRAF mutation (Kumar et al., 2004; Pollock et al., 2003; Saldanha et al., 2004; Uribe et al., 2003; Yazdi et al., 2003).”
BackgroundVemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
Larkin, J., & Fisher (2012) · Cancer Management and Research · doi:10.2147/cmar.s25284 · Cited by 73
Juszczak, A. M., Wölfle, U., Končić, M. Z., & Tomczyk, M. (2022) · Medicinal Research Reviews · doi:10.1002/med.21880 · Cited by 67
“Both of the described mutations in the MAPK pathway are associated with uncontrolled proliferation and metastatic development of primary melanoma, but these mutants may be used as targets for the development of anti‐ melanoma drugs.(88,93,96,97) The least common MAPK mutations include those correlated with suppressor…”
BackgroundMelanoma therapeutics: a literature review
Dhanyamraju, P. K., & Patel, T. (2022) · Journal of Biomedical Research · doi:10.7555/jbr.36.20210163 · Cited by 76
Pinzani, P., Salvianti, F., Cascella, R., Massi, D., GIORGI, V. D., Pazzagli, M., & Orlando, C. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.05.024 · Cited by 65
Patterns of genomic evolution in advanced melanoma
Birkeland, E. E., Zhang, S., Poduval, D. B., Geisler, J., Nakken, S., Vodák, D., Meza‐Zepeda, L. A., Hovig, E. J., Myklebost, O., Knappskog, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05063-1 · Cited by 65
Targeting Oncogenic BRAF in Human Cancer
Pratilas, C. A., Xing, F., & Solit, D. B. (2010) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2011_162 · Cited by 61
“Activating BRAF mutations are, however, present in the majority of melanocytic nevi, benign skin lesions that rarely progress to melanoma (Pollock et al. 2003).”
BackgroundPreto, A., Figueiredo, J., Velho, S., Ribeiro, A., Soares, P., Oliveíra, C., & Seruca, R. (2007) · The Journal of Pathology · doi:10.1002/path.2295 · Cited by 60
Absence of Distinguishing Senescence Traits in Human Melanocytic Nevi
Tran, S. L., Haferkamp, S., Scurr, L. L., Gowrishankar, K., Becker, T. M., Desilva, C., Thompson, J. F., Scolyer, R. A., Kefford, R. F., & Rizos, H. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.126 · Cited by 69
Greene, V. R., Johnson, M. M., Grimm, E. A., & Ellerhorst, J. A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.374 · Cited by 60
“Mutations of RAS and RAF genes, particularly NRAS exon 2 and BRAF exon 15, have been identified with high frequency in nevi, cutaneous melanomas, and melanoma metastases (Davies et al., 2002; Pollock et al., 2003; Uribe et al., 2003; Houben et al., 2004; Kumar et al., 2004; Akslen et al., 2005; Goydos et al., 2005; Ed…”
Audrito, V., Managò, A., Vecchia, S. L., Zamporlini, F., Vitale, N., Baroni, G., Cignetto, S., Serra, S., Bologna, C., Stingi, A., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx198 · Cited by 71
“As expected (17,23), BiR cells were insensitive to BRAFi (Figure 1A) and showed constitutive activation of the MAPK axis, downstream of BRAF (Supplementary Figure 1, available online).”
BackgroundCopper chaperone ATOX1 is required for MAPK signaling and growth in BRAF mutation-positive melanoma
Kim, Y., Bond, G. J., Tsang, T., Posimo, J. M., Busino, L., & Brady, D. C. (2019) · Metallomics · doi:10.1039/c9mt00042a · Cited by 63
Haluska, F. G., Pemberton, T., Ibrahim, N., & Kalinsky, K. M. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.09.011 · Cited by 67
Melanoma Skin Cancer: A Comprehensive Review of Current Knowledge
Caraviello, C., Nazzaro, G., Tavoletti, G., Boggio, F. L., Denaro, N., Murgia, G., Passoni, E., Benzecry, V., & Marzano, A. V. (2025) · Cancers · doi:10.3390/cancers17172920 · Cited by 77
Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma
Pearlstein, M. V., Zedek, D. C., Ollila, D. W., Treece, A. L., Gulley, M. L., Groben, P. A., & Thomas, N. E. (2014) · Journal of Cutaneous Pathology · doi:10.1111/cup.12364 · Cited by 61
“This finding supports the presence of BRAF V600E mutant protein in nevi, indicating that BRAF mutations alone are not sufficient for melanoma pathogenesis.(3) Therefore, this immunostain should not be considered diagnostic for melanoma.”
ResultTom, W. L., Hsu, J. W., Eichenfield, L. F., & Friedlander, S. F. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.12.063 · Cited by 59
“B-raf mutations have also been demonstrated in common acquired nevi and dysplastic nevi, suggesting that they may play a potential role in early progression of melanocytic neoplasia, but alone they are insufficient to account for melanoma tumorigenesis.(36) The presence of B-raf mutations therefore cannot clearly deli…”
IGFBP7 Is Not Required for B-RAF-Induced Melanocyte Senescence
Scurr, L. L., Pupo, G. M., Becker, T. M., Lai, K., Schrama, D., Haferkamp, S., Irvine, M., Scolyer, R. A., Mann, G. J., Becker, J. C., et al. (2010) · Cell · doi:10.1016/j.cell.2010.04.021 · Cited by 63
“Indeed, constitutively activating mutations affecting the N-RAS or B-RAF kinase components of the mitogen-activated protein kinase (MAPK) pathway are found in over 80% of benign nevi (Bauer et al., 2007; Papp et al., 1999; Pollock et al., 2003).”
Modelling oncogenic Ras/Raf signalling in the mouse
Karreth, F. A., & Tuveson, D. A. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.12.006 · Cited by 59
Genetic predisposition to melanoma
Hawkes, J. E., Truong, A., & Meyer, L. J. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.08.003 · Cited by 69
“Secondly, this identical mutation is seen in well over half of all benign nevi.(86) Activating BRAF mutations provide a target for small molecule inhibitors and has allowed the rapid development of drugs targeting this mutation, as well as other points in the MAPK pathway, leading to”
BackgroundBedognetti, D., Roelands, J. P., Decock, J. V., Wang, E., & Hendrickx, W. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170142 · Cited by 61
The paradox of cancer genes in non-malignant conditions: implications for precision medicine
Adashek, J. J., Kato, S., Lippman, S. M., & Kurzrock, R. (2020) · Genome Medicine · doi:10.1186/s13073-020-0714-y · Cited by 62
“An example that defies the tissue- or histology-context hypothesis is BRAF V600E, a known oncogenic driver that occurs in around 80% of benign nevi [3, 4].”
BackgroundCozzi, S.-J., Parsons, P. G., Ogbourne, S. M., Pedley, J., & Boyle, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0348 · Cited by 60
“Extensive evidence has supported a role for the MAPK pathway in proliferation and malignancy of several tumor types, with NRAS and BRAF mutations denoted as early signatures of malignancy in nevi and melanoma ( 44 ).”
BackgroundCutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT
Daniotti, M., Ferrari, A., Frigerio, S., Casieri, P., Miselli, F., Zucca, E., Collini, P., Torre, G. D., Manoukian, S., Peissel, B., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.422 · Cited by 63
“This alteration was detected in pediatric lesions as well as in familial melanoma lesions and in nevi from these patients, confirming previously reported data (Pollock et al., 2003; Gast et al., 2005).”
ResultSchönleben, F., Qiu, W., Allendorf, J., Chabot, J. A., Remotti, H. E., & Su, G. H. (2009) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-009-0917-4 · Cited by 59
“BRAF mutations have been detected in the early stages of colon cancer and melanoma development.(41,42) These observations are in concordance with our results, where both BRAF mutations occurred in periampullary adenomas with CIS, indicating that BRAF mutation, when present, is an early event in tumorigenesis.”
ResultTherapy for metastatic melanoma: an overview and update
Boyle, G. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.25 · Cited by 62
Bhandarkar, S. S., Bromberg, J., Carrillo, C. O., Selvakumar, P., Sharma, R. K., Perry, B. N., Govindarajan, B., Fried, L. E., Sohn, A. M., Reddy, K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0405 · Cited by 64
“Many melanomas carry mutations in B-raf, which cause constitutive activation of MAP kinase (1; 2).”
Lack of BRAF Mutations in Spitz nevi
Gill, M., Renwick, N. M., Silvers, D. N., & Celebi, J. T. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22530.x · Cited by 58
“A high frequency of V599 codon substitution (73–82%) has been reported in a variety of common melanocytic nevi including compound, junctional, intradermal, congenital, and dyplastic nevi”
BackgroundTandem BRAF Mutations in Primary Invasive Melanomas
Thomas, N. E., Alexander, A., Edmiston, S. N., Parrish, E., Millikan, R. C., Berwick, M., Groben, P., Ollila, D. W., Mattingly, D., & Conway, K. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22523.x · Cited by 57
“…melanomas.1 In addition, BRAF 599 double mutations have been reported in two other primary melanomas, a few metastatic melanomas, a melanoma cell line, and a congenital nevus (Davies et al, 2002; Pollock et al, 2003; Dong et al, 2003; Gorden et al, 2003; Kumar et al, 2003; Uribe et al, 2003).”
BackgroundArgast, G. M., Croy, C. H., Couts, K. L., Zhang, Z., Litman, E. S., Chan, D. C. F., & Ahn, N. G. (2009) · Oncogene · doi:10.1038/onc.2009.133 · Cited by 66
“High frequencies of B-Raf mutations have been observed in nevoid/RGP specimens as well as advanced tumors (Omholt et al., 2003; Pollock et al., 2003).”
Genetics and genomics of melanoma
Ghosh, P., & Chin, L. (2009) · Expert Review of Dermatology · doi:10.1586/edm.09.2 · Cited by 72
Friedman, R. J., Farber, M. J., Warycha, M. A., Papathasis, N., Miller, M. K., & Heilman, E. R. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.008 · Cited by 79
Understanding spitzoid tumours: new insights from molecular pathology
Forno, P. D., Fletcher, A. A., Pringle, J. H., & Saldanha, G. S. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08207.x · Cited by 60
Targeting BRAFV600E in thyroid carcinoma: therapeutic implications
Mitsiades, C. S., Negri, J. M., McMullan, C. J., McMillin, D. W., Sozopoulos, E., Fanourakis, G., Voutsinas, G. E., Tseleni‐Balafouta, S., Poulaki, V., Batt, D. B., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0449 · Cited by 62
Lee, J. J., Sholl, L. M., Lindeman, N. I., Granter, S. R., Laga, A. C., Shivdasani, P., Chin, G., Luke, J. J., Ott, P. A., Hodi, F. S., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0091-3 · Cited by 62
“However, soon after the discovery of frequent BRAF V600E mutations in melanoma, the same mutation was found at higher frequencies in benign and dysplastic melanocytic nevi [4].”
BackgroundBlood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection
Pantel, K. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002205 · Cited by 56
Melanoma pathology: new approaches and classification*
Yeh, I., & Bastian, B. C. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20427 · Cited by 69
Absence of V599E BRAF mutations in desmoplastic melanomas
Davison, J. M., Rosenbaum, E., Barrett, T. L., Goldenberg, D., Hoque, M. O., Sidransky, D., & Westra, W. H. (2005) · Cancer · doi:10.1002/cncr.20861 · Cited by 56
“This hot spot was chosen because the reported BRAF-activating mutations in cutaneous nevi and cutaneous melanoma occur almost exclusively at this position.(12,13) Admittedly, the targeted assay employed in the current study does not permit detection of the small proportion of non-V599E mutations that cluster in and ar…”
BackgroundMesteri, I., Bayer, G., Meyer, J., Capper, D., SCHOPPMANN, S. F., von Deimling, A., & Birner, P. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.126 · Cited by 56
New and evolving concepts of melanocytic nevi and melanocytomas
Yeh, I. (2019) · Modern Pathology · doi:10.1038/s41379-019-0390-x · Cited by 58
Fujii, S., Ishibashi, T., Kokura, M., Fujimoto, T., Matsumoto, S., Shidara, S., Kurppa, K. J., Pape, J., Catón, J., Morgan, P. R., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5814 · Cited by 64
“Similarly, BRAFV600E mutations were observed in 39 (89%) of 44 human cases of benign naevi, indicating that BRAF activation alone is not sufficient for the development of melanoma [46].”
BackgroundCasula, M., Colombino, M., Satta, M. P., Cossu, A., Ascierto, P. A., Bianchi‐Scarrà, G., Castiglia, D., Budroni, M., Rozzo, C., Manca, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.112 · Cited by 56
“BRAF somatic mutations were also found in majority of histologically different nevi [22], implying that, although a crucial step in the initiation of melanocytic transformation, mutation of this gene alone is insufficient for the development of melanoma.”
BackgroundRaeve, L. E. D., Claes, A., Ruiter, D. J., van Muijen, G. N. P., Roseeuw, D. I., & van Kempen, L. C. L. T. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.07055.x · Cited by 56
Nagore, E., Estrada, R. B., Requena, C., Serra-Guillén, C., Martorell, A., Hueso, L., Llombart, B., Sanmartín, O., & Guillén, C. (2009) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(09)70536-8 · Cited by 58
Zebrafish models of cancer: progress and future challenges
Yen, J., White, R. M., & Stemple, D. L. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.003 · Cited by 54
Epigenetics and Dermatological Disease
Millington, G. W. M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1835 · Cited by 58
Melanoma: Clinical Features and Genomic Insights
Hawryluk, E. B., & Tsao, H. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a015388 · Cited by 69
“In 2003, Pollock et al. (2003) identified BRAF mutations among 80% of primary melanomas, 68% of melanoma metastases, and 82% of nevi tested suggesting that the activating BRAF mutation may have a role in initiation of melanocytic proliferation, but is not sufficient for melanomagenesis.”
BackgroundMutational Analysis of the BRAF Gene in Transitional Cell Carcinoma of the Bladder
Boulalas, I., Zaravinos, A., Delakas, D., & Spandidos, D. A. (2009) · The International Journal of Biological Markers · doi:10.5301/jbm.2009.4457 · Cited by 54
“Additionally, BRAF mutations such as the V600E were described in KRAS-negative colon carcinomas, suggesting that BRAF/KRAS-activating mutations are alternative genetic events in colon cancer (5-7).”
BackgroundRegulation of tissue‐ and stimulus‐specific cell fate decisions by p53 in vivo
Jackson, J. G., Post, S. M., & Lozano, G. (2011) · The Journal of Pathology · doi:10.1002/path.2783 · Cited by 53
Larsen, A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13207 · Cited by 55
Mouse models of UV-induced melanoma: genetics, pathology, and clinical relevance
Day, C., Marchalik, R., Merlino, G. T., & Michael, H. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.155 · Cited by 61
Ultraviolet light and melanoma
Craig, S., Earnshaw, C. H., & Virós, A. (2018) · The Journal of Pathology · doi:10.1002/path.5039 · Cited by 64
“of acquired benign melanocytic naevi [61], which predominantly harbour a BRAF mutation and constitute an independent risk factor for melanoma [34,62].”
BackgroundHairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment
Troussard, X., Maître, E., & Cornet, É. (2021) · American Journal of Hematology · doi:10.1002/ajh.26390 · Cited by 63
“mutations while never experiencing malignant transformation (Table 1).(46) These data suggest that cooperating genetic and/or epigenetic events are required to facilitate malignant transformation.”
BackgroundTargeting BRAF in melanoma: Biological and clinical challenges
Mandalà, M., & Voit, C. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.01.003 · Cited by 61
Selective evolutionary pressure from the tissue microenvironment drives tumor progression
Smalley, K. S. M., Brafford, P. A., & Herlyn, M. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.06.002 · Cited by 75
“The findings in nevi are made more interesting by the fact that these same benign nevi harbor the V600E mutation of BRAF in 21–80% of cases [ 40 ,41].”
BackgroundGenetics of melanoma tumorigenesis
Singh, M., Lin, J., Hocker, T. L. H., & Tsao, H. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08316.x · Cited by 62
Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells
Smith, A. G., Lim, W., Pearen, M. A., Muscat, G. E. O., & Sturm, R. A. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00843.x · Cited by 56
“Notably, a similarly high proportion of BRAF mutations are detected in benign nevi illustrating that while these mutations are capable of initiating melanomagenesis, they are alone insufficient for complete cellular transformation (Omholt et al., 2003; Pollock et al., 2003).”
BackgroundOncogenes in melanoma: An update
Kunz, M. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.12.002 · Cited by 61
BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
Sullivan, R. J., & Flaherty, K. T. (2011) · Journal of Skin Cancer · doi:10.1155/2011/423239 · Cited by 53
“Approximately 70–80% of acquired melanocytic nevi and 40–60% of malignant melanoma contain a BRAF mutation, the vast majority of which result in a single amino acid change at codon 600 (BRAFV600E) [3, 4].”
BackgroundBiology, Therapy and Implications of Tumor Exosomes in the Progression of Melanoma
Isola, A. L., Eddy, K., & Chen, S. (2016) · Cancers · doi:10.3390/cancers8120110 · Cited by 67
“An example of this is a single-base missense transversion causes the replacement of valine with glutamic acid at amino acid residue 600 in BRAF that is detected in about 85% of nevi and melanoma [11,12].”
BackgroundSystemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma
Mor, J. M., & Heindl, L. M. (2016) · Ocular Oncology and Pathology · doi:10.1159/000452473 · Cited by 53
Larsen, A. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13100 · Cited by 57
“BRAF V600E mutations have been identified in up to 80% of cutaneous nevi, suggesting that BRAF mutations are one of the first of many genetic events in the formation and progression of cutaneous melanoma (Pollock et al. 2003; Dahl & Guldberg 2007).”
BackgroundHigh- and low-penetrance cutaneous melanoma susceptibility genes
Fargnoli, M. C., Argenziano, G., Zalaudek, I., & Peris, K. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.5.657 · Cited by 62
Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma
Mihic‐Probst, D., Perren, A. A., Schmid, S., Saremaslani, P., Komminoth, P., & Heitz, P. U. (2004) · PubMed · doi:10.5167/uzh-111579 · Cited by 53
Role of miRNA in Melanoma Development and Progression
Poniewierska-Baran, A., Słuczanowska-Głąbowska, S., Małkowska, P., Sierawska, O., Zadroga, Ł., Pawlik, A., & Niedźwiedzka‐Rystwej, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010201 · Cited by 61
“Their levels correlate with the clinical efficacy of ICI, which is why miRNAs are being considered as new therapeutic strategies to overcome BRAFi and ICI resistance.”
BackgroundInfluentialInferring mutational timing and reconstructing tumour evolutionary histories
Turajlic, S., McGranahan, N., & Swanton, C. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.03.005 · Cited by 54
“U N C O R R E C both BRAF[94] and NRAS[95] mutations are found in acquired naevi, which are precursors to melanoma.”
Backgroundc-kit gene mutation and CD117 expression in human anorectal melanomas
Ni, S., Huang, D., Chen, X., Huang, J., Kong, Y., Xu, Y., Du, X., & Sheng, W. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.08.005 · Cited by 52
“Several findings indicate that activation of the mitogen-activated protein kinase pathway is an important phenomenon in melanoma and thus a possible target for future therapies [27,28].”
Background3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines
Qin, J.-Z., Xin, H., & Nickoloff, B. J. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.04.126 · Cited by 54
“Rather than focusing on traditional targets derived from genomic approaches such as the BRAF mutation [2], or alterations in signal transduction pathways [3], the altered metabolome of melanoma was targeted.”
BackgroundCui, Y., Borysova, M. K., Johnson, J., & Guadagno, T. M. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1491 · Cited by 53
van Rooijen, E., Fazio, M., & Zon, L. I. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12592 · Cited by 62
“BRAF was first identified in 2002 to be the most frequently mutated gene in melanoma (Davies et al., 2002); however, as both benign nevi and melanoma commonly express BRAFV600E, other lesions are required to promote melanoma (Davies et al., 2002; Pollock et al., 2003).”
BackgroundNew techniques in dermatopathology that help to diagnose and prognosticate melanoma
Carlson, J. A., Ross, J. S., & Slominski, A. T. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.007 · Cited by 55
Macrophage Inhibitory Cytokine-1 Regulates Melanoma Vascular Development
Huh, S. J., Chung, C.-Y., Sharma, A. K., & Robertson, G. P. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090963 · Cited by 55
“The mitogen-activated protein (MAP) kinase pathway is deregulated in 60% of sporadic melanoma through mutation of B-Raf into a constitutively active V600E (B-Raf) form.(14,15) This activated pathway in turn regulates diverse processes aiding tumor development such as proliferation, apoptosis, metastasis, and angiogene…”
Dermatoscopy of "dysplastic nevi": a beacon in diagnostic darkness.
Roesch, A., Burgdorf, W. H. C., Stolz, W., Landthaler, M., & VOGT, T. M. (2006) · PubMed · Cited by 52
Variations of BRAF mutant allele percentage in melanomas
Hélias‐Rodzewicz, Z., Funck‐Brentano, E., Baudoux, L., Jung, C. K., Zimmermann, U. S., Marin, C., Clérici, T., Gall, C. L., Peschaud, F., Taly, V., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1515-3 · Cited by 54
“A similar frequency of BRAF mutations in the same types of nevi has already been reported [37].”
BackgroundMolecular Platforms Utilized to Detect BRAF V600E Mutation in Melanoma
Curry, J. L., Torres-Cabala, C. A., Tetzlaff, M. T., Bowman, C., & Prieto, V. G. (2012) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/j.sder.2012.07.007 · Cited by 51
“8,12,13 However, approximately 80% of melanocytic nevi also harbor mutant BRAF V600E—identical to the most common BRAF mutation in melanoma.”
BackgroundRole of EZH2 histone methyltrasferase in melanoma progression and metastasis
Mahmoud, F. A., Shields, B. D., Makhoul, I., Hutchins, L. F., Shalin, S. C., & Tackett, A. J. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1167291 · Cited by 57
The T1799A BRAF Mutation Is Present in Iris Melanoma
Henriquez, F. L., Janssen, C. S., Kemp, E., & Roberts, F. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0440 · Cited by 58
“and have also been detected in up to 82% of melanocytic nevi.(15) The mutation has also been reported in 22% to 40% of conjunctival melanomas.”
BackgroundGenetics of papillary thyroid cancer initiation: implications for therapy.
Fagin, J. A. (2005) · PubMed · Cited by 61
Is there a role for genetic testing in patients with melanoma?
Kefford, R. F., & Mann, G. J. (2003) · Current Opinion in Oncology · doi:10.1097/00001622-200303000-00007 · Cited by 51
B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma
Shepherd, C., Puzanov, I. J., & Sosman, J. A. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0095-2 · Cited by 58
“However, the same mutation was also observed in well over 75% of benign nevi (hyperplastic growths) [ 16 , 17].”
BackgroundSchultz, J., Ibrahim, S. M., Vera, J., & Kunz, M. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-53 · Cited by 55
“ever, since also benign melanocytic nevi as classical melanoma precursor lesions showed a high percentage of activating BRAF mutations, further molecular mechanisms might contribute to primary tumor development [9,10].”
Mutational status of naevus-associated melanomas
Shitara, D. I., Tell‐Martí, G., Bádenas, C., Enokihara, M. M. S. S., Alós, L., Larque, A. B., Michalany, N. S., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13829 · Cited by 57
BUSAM, K. J., Wanna, M., & Wiesner, T. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.1529 · Cited by 53
Precision Medicine and Melanoma: Multi-Omics Approaches to Monitoring the Immunotherapy Response
Valenti, F., Falcone, I., Ungania, S., Desiderio, F., Giacomini, P., Bazzichetto, C., Conciatori, F., Gallo, E., Cognetti, F., Ciliberto, G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083837 · Cited by 60
“It is clear that most of the benign lesions present the alteration of v-Raf murine sarcoma viral oncogene homolog B (BRAF) in the codon V600E (sufficient for the nevus formation); but, for melanoma development, BRAF mutation is not sufficient because the disease progression is bound to concomitant alteration in other…”
Background
Metadata
- Authors
- Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., & Meltzer, P. S.
- Affiliations
- National Institutes of Health (US)
- QIMR Berghofer Medical Research Institute (AU)
- The University of Western Australia (AU)
- Corresponding author
- Meltzer, Paul S.
- ORCID
- Venue
- Nature Genetics
- Published
- 2002-11-25
- Volume
- 33
- Issue
- 1
- Pages
- 19-20
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W1565041471
- Cited by
- 1,730
- References
- 4
- Citations by year
- 2026: 15 · 2025: 24 · 2024: 40 · 2023: 49 · 2022: 46 · 2021: 73 · 2020: 58 · 2019: 73 · 2018: 67 · 2017: 87 · 2016: 79 · 2015: 87 · 2014: 84 · 2013: 104 · 2012: 92
- FWCI
- 25.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Keywords
- BRAF mutation, melanocytic nevi, melanoma, melanoma metastasis, RAS/MAPK pathway, carcinogenesis
- MeSH terms
- Cell Transformation, Neoplastic, DNA Mutational Analysis, Gene Frequency, Humans, Melanoma, Nevus, Signal Transduction, Polymerase Chain Reaction, Genetic Predisposition to Disease, Mutation, Missense, Oncogene Proteins v-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.